BPC157 - Stealth Labs

The early development of BPC-157 began under the guidance of Croatian scientist Predrag Sikiric in 1992. Designed as a synthetic peptide based on a natural gastric compound, it was initially investigated for its potential role in healing soft tissues. The work was financially supported by the pharmaceutical company Pliva until 2005, when the project was discontinued. Although Merck expressed interest in its patents, no licensing deal was finalized. BPC-157 later became popular in the research market, where Diagen of Slovenia took the lead in production.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about BPC157 by Stealth Labs, consult with your doctor or healthcare professional.